ABPI President Haseeb Ahmad says that genome sequencing and advanced therapies give hope to people with rare diseases and their families – we have to get them into the hands of patients.
Nicola Redfern, General Manager of bluebird bio in the UK, describes the commercial challenges for rare disease medicines in the UK and reflects on the opportunities of gene therapies.
Dr Lucy McKay, CEO of the charity Medics4Rare Diseases tells us why their new educational module – Rare Disease 101 - should be essential for all healthcare professionals.
Thalassaemia major is a serious, genetic blood disorder. Roanna Maharaj was diagnosed with a severe form of the disease as a baby in the Caribbean. This is her story.
In its second annual clinical trials report launched this week, the ABPI is calling for the research community to work with Government, funders, and the public to tackle issues around diversity and inclusion in research.
The ABPI partnered with Reform on an event on the NICE Methods Review, titled 'A Global Science Superpower: The Future of Medicines Valuation.
ABPI Chief Executive talks about the importance of vaccines, as ABPI launches its new campaign, #ValuingVaccines.
With 10 million people a year projected to die from antibiotic-resistant infections by 2050, it’s important that all partners, including the pharmaceutical industry, step up and work together to tackle this issue.
The Taskforce for Lung Health has been awarded Charity Collaboration of the Year at the Charity Times awards. Su Jones, NHS Engagement Partner at the ABPI and Dr Alison Cook, Chair of the Taskforce for Lung Health, explain the importance of the Taskforce and look to the future of its work.
As Gavi marks its twentieth anniversary, a new report from the ABPI and IFPMA looks at the past successes of the Vaccines Alliance and what the future holds.